Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Sareum secures funding for drug programme

The company has raised £850,000 before expenses, which will be used to develop potential treatments for cancer and autoimmune diseases
researcher filling testtube
“We believe we have strong candidates with optimised profiles in these areas and are focused on advancing these into preclinical development towards clinical trials,” said chief executive, Dr Tim Mitchell.

Sareum Holdings Plc (LON:SAR) said it had completed a share placing that has raised £850,000.

The proceeds will be used for working capital purposes and to fund the development of its TYK2/JAK1 targets, which are being developed to treat autoimmune disease and cancer.

READ: Sareum selects potential anti-cancer molecule for further development

“We believe we have strong candidates with optimised profiles in these areas and are focused on advancing these into preclinical development towards clinical trials,” said chief executive, Dr Tim Mitchell.

“These new funds, added to our current cash, will enable us to advance these studies and build up the evidence required to facilitate a licensing agreement at an optimal value."

The stock, which closed Thursday at 0.78p, was sold in placing for 0.65p a share.

View full SAR profile View Profile

Sareum Holdings Plc Timeline

Related Articles

cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma
3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use